Dalbavancin to prevent infections in kids with leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if an antibiotic called dalbavancin can help prevent serious bacterial infections in children and young adults with high-risk leukemia whose immune systems are weakened by treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 25 years old or younger
- You are being treated for acute myeloid leukemia (AML) or relapsed acute lymphoblastic leukemia (ALL) at St. Jude
- Your treatment is expected to cause very low white blood cell counts (neutropenia) that last more than a week
- You plan to receive care at St. Jude for at least 56 days after joining the study
- If you are female and 9 or older, you must have a negative pregnancy test before starting the study drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving antibiotics to prevent infections helps patients with myelodysplastic syndromes or acute myeloid leukemia who are starting a specific type of chemotherapy called hypomethylating agents. Preventing infections could help patients stay healthier during treatment.
This study tests a new way to monitor and treat AML in children and young adults after their first chemotherapy. It aims to improve outcomes by closely tracking the disease and adjusting treatment as needed.
This trial tests a combination of two oral drugs (venetoclax and decitabine/cedazuridine) for children and teens whose acute myeloid leukemia (AML) has returned or not improved after prior treatment. The goal is to find a safe dose and see if the drugs can help shrink or control the leukemia.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
This trial tests whether taking the antibiotic levofloxacin can prevent a first serious infection (febrile neutropenia) in children with ALL during the first weeks of chemotherapy. It aims to keep kids safer during treatment.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.